Colin G Steward1,2, Sarah J Groves2, Carolyn T Taylor3, Melissa K Maisenbacher4, Birgitta Versluys5, Ruth A Newbury-Ecob6, Hulya Ozsahin7, Michaela K Damin8, Valerie M Bowen9, Katherine R McCurdy9, Michael C Mackey10, Audrey A Bolyard11, David C Dale12. 1. NHS Specialised Services Barth Syndrome Service, Royal Hospital for Children. 2. School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK. 3. Department of Pediatrics, Division of Cardiology, Children's Hospital, Medical University of South Carolina, Charleston, South Carolina. 4. Natera, San Carlos, California, USA. 5. Department of Immunology/Hematology and BMT, University Medical Center Utrecht, Utrecht, The Netherlands. 6. Department of Clinical Genetics, St Michael's Hospital, Bristol, UK. 7. Former: University Children's Hospital, Geneva. 8. Barth Syndrome Trust, Romsey, UK. 9. Barth Syndrome Foundation, Inc., Larchmont, New York, USA. 10. Departments of Physiology, Physics, and Mathematics, Centre for Applied Mathematics in Bioscience and Medicine, McGill University, Montreal, Québec, Canada. 11. Severe Chronic Neutropenia International Registry. 12. Department of Medicine, University of Washington, Seattle, Washington, USA.
Abstract
PURPOSE OF REVIEW: Barth syndrome (BTHS) is an X-linked disease characterized by defective remodeling of phospholipid side chains in mitochondrial membranes. Major features include neutropenia, dilated cardiomyopathy, motor delay and proximal myopathy, feeding problems, and constitutional growth delay. We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF). RECENT FINDINGS: In 88 patients with BTHS, neutropenia, that is, at least one count below 1.5 × 10/l, was detected in 74 (84%) and 44% had severe chronic neutropenia, with multiple counts below 0.5 × 10/l. The pattern of neutropenia varied between intermittent and unpredictable, chronic and severe, or cyclical with mathematically regular oscillations. Monocytosis, that is, monocytes more than 1.0 × 10/l, was observed at least once in 64 of 85 (75%) patients. G-CSF was administered to 39 of 88 patients (44%). Weekly average G-CSF doses ranged from 0.12 to 10.92 μg/kg/day (mean 1.16 μg/kg/day, median 1.16 μg/kg/day). Antibiotic prophylaxis was additionally employed in 21 of 26 neutropenic patients. Pretreatment bone marrow evaluations predominantly showed reduced myeloid maturation which normalized on G-CSF therapy in seven of 13 examined. Consistent clinical improvement, with reduced signs and symptoms of infections, was observed in response to prophylactic G-CSF ± prophylactic antibiotics. However, despite G-CSF and antibiotics, one adult patient died with multiple infections related to indwelling medical devices and gastrostomy site infection after 15.5 years on G-CSF and a pediatric patient required gastrostomy removal for recurrent abdominal wall cellulitis. SUMMARY: BTHS should be considered in any men with neutropenia accompanied by any of the characteristic features of this syndrome. Prophylaxis with G-CSF ± antibiotics prevents serious bacterial infections in the more severe neutropenic patients although infections remain a threat even in patients who are very compliant with therapy, especially in those with indwelling devices.
PURPOSE OF REVIEW: Barth syndrome (BTHS) is an X-linked disease characterized by defective remodeling of phospholipid side chains in mitochondrial membranes. Major features include neutropenia, dilated cardiomyopathy, motor delay and proximal myopathy, feeding problems, and constitutional growth delay. We conducted this review of neutropenia in BTHS to aid in the diagnosis of this disease, and to improve understanding of both the consequences of neutropenia and the benefits of treatment with granulocyte colony-stimulating factor (G-CSF). RECENT FINDINGS: In 88 patients with BTHS, neutropenia, that is, at least one count below 1.5 × 10/l, was detected in 74 (84%) and 44% had severe chronic neutropenia, with multiple counts below 0.5 × 10/l. The pattern of neutropenia varied between intermittent and unpredictable, chronic and severe, or cyclical with mathematically regular oscillations. Monocytosis, that is, monocytes more than 1.0 × 10/l, was observed at least once in 64 of 85 (75%) patients. G-CSF was administered to 39 of 88 patients (44%). Weekly average G-CSF doses ranged from 0.12 to 10.92 μg/kg/day (mean 1.16 μg/kg/day, median 1.16 μg/kg/day). Antibiotic prophylaxis was additionally employed in 21 of 26 neutropenicpatients. Pretreatment bone marrow evaluations predominantly showed reduced myeloid maturation which normalized on G-CSF therapy in seven of 13 examined. Consistent clinical improvement, with reduced signs and symptoms of infections, was observed in response to prophylactic G-CSF ± prophylactic antibiotics. However, despite G-CSF and antibiotics, one adult patient died with multiple infections related to indwelling medical devices and gastrostomy site infection after 15.5 years on G-CSF and a pediatric patient required gastrostomy removal for recurrent abdominal wall cellulitis. SUMMARY:BTHS should be considered in any men with neutropenia accompanied by any of the characteristic features of this syndrome. Prophylaxis with G-CSF ± antibiotics prevents serious bacterial infections in the more severe neutropenicpatients although infections remain a threat even in patients who are very compliant with therapy, especially in those with indwelling devices.
Authors: Charlotte Thiels; Martin Fleger; Martina Huemer; Richard J Rodenburg; Frederic M Vaz; Riekelt H Houtkooper; Tobias B Haack; Holger Prokisch; René G Feichtinger; Thomas Lücke; Johannes A Mayr; Saskia B Wortmann Journal: JIMD Rep Date: 2016-01-03
Authors: Vahagn Makaryan; Willem Kulik; Frederic M Vaz; Christopher Allen; Yigal Dror; David C Dale; Andrew A Aprikyan Journal: Eur J Haematol Date: 2011-12-04 Impact factor: 2.997
Authors: Sarah L N Clarke; Ann Bowron; Iris L Gonzalez; Sarah J Groves; Ruth Newbury-Ecob; Nicol Clayton; Robin P Martin; Beverly Tsai-Goodman; Vanessa Garratt; Michael Ashworth; Valerie M Bowen; Katherine R McCurdy; Michaela K Damin; Carolyn T Spencer; Matthew J Toth; Richard I Kelley; Colin G Steward Journal: Orphanet J Rare Dis Date: 2013-02-12 Impact factor: 4.123
Authors: David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte Journal: Curr Opin Hematol Date: 2020-01 Impact factor: 3.284
Authors: Hana M Zegallai; Ejlal Abu-El-Rub; Edgard M Mejia; Genevieve C Sparagna; Laura K Cole; Aaron J Marshall; Grant M Hatch Journal: Cell Tissue Res Date: 2022-09-21 Impact factor: 4.051
Authors: Mindong Ren; Paighton C Miller; Michael Schlame; Colin K L Phoon Journal: Am J Physiol Heart Circ Physiol Date: 2019-10-11 Impact factor: 4.733
Authors: Mauro Corrado; Joy Edwards-Hicks; Matteo Villa; Lea J Flachsmann; David E Sanin; Maaike Jacobs; Francesc Baixauli; Michal Stanczak; Eve Anderson; Mai Azuma; Andrea Quintana; Jonathan D Curtis; Thomas Clapes; Katarzyna M Grzes; Agnieszka M Kabat; Ryan Kyle; Annette E Patterson; Ramon Klein Geltink; Borko Amulic; Colin G Steward; Douglas Strathdee; Eirini Trompouki; David O'Sullivan; Edward J Pearce; Erika L Pearce Journal: Cell Metab Date: 2020-12-01 Impact factor: 27.287
Authors: Jihee Sohn; Jelena Milosevic; Thomas Brouse; Najihah Aziz; Jenna Elkhoury; Suya Wang; Alexander Hauschild; Nick van Gastel; Murat Cetinbas; Sara F Tufa; Douglas R Keene; Ruslan I Sadreyev; William T Pu; David B Sykes Journal: Blood Adv Date: 2022-04-26